<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039896</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_VCM_101</org_study_id>
    <nct_id>NCT01039896</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of SLM0807 and HKB0701 in Healthy Subjects</brief_title>
  <official_title>An Open-label, Randomized, Crossover Study to Evaluate the Safety and Pharmacokinetics After Multiple Administration of SLM0807 Alone and Multiple Co-administration of HKB0701/SLM0807 in Korean Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether HKB0701 alters pharmacokinetics of SLM0807.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Css,max and AUCinf</measure>
    <time_frame>up to 24hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCtau, AUCt, Tmax</measure>
    <time_frame>up to 24hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLM0807</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLM0807 and HKB0701</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : SLM0807, Period II : HKB0701 and SLM0807</intervention_name>
    <arm_group_label>Group1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : HKB0710 and SLM0807, Period II : SLM0807</intervention_name>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers who are in age range of 20-50years and the weight range is not&#xD;
             exceed Â±20% of ideal weight. Ideal weight = [height -100]*0.9&#xD;
&#xD;
          -  Subjects with no history of any significant chronic disease&#xD;
&#xD;
          -  Judged to be in good health on the basis of their vital sign, ECG, physical exam and&#xD;
             routine laboratory data&#xD;
&#xD;
          -  Available for the entire study period&#xD;
&#xD;
          -  Willing to adhere to protocol requirements and sign a informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have taken any drugs to induce or inhibit hepatic enzyme activity within&#xD;
             30days prior to drug administration&#xD;
&#xD;
          -  Subjects who have symptom of an acute illness within 4 weeks prior to drug&#xD;
             administration&#xD;
&#xD;
          -  Subjects with a history of clinically significant allergies including drug allergies&#xD;
&#xD;
          -  Subjects whose clinical laboratory test values are outside the accepted normal&#xD;
             range(Especially,AST or ALT &gt;1.25 times to normal range or total bilirubin &gt; 1.5times&#xD;
             to normal range)&#xD;
&#xD;
          -  Subjects with a history of drug, caffeine or alcohol abuse (caffeine drink &gt;5cups&#xD;
             /day, alcohol &gt;30g/day)&#xD;
&#xD;
          -  Heavy smoker ( &gt;10cigarettes/day)&#xD;
&#xD;
          -  Subjects who have had a diet known to interfere with the absorption, distribution,&#xD;
             metabolism or excretion of drugs (especially, consumption of grapefruit juice)&#xD;
&#xD;
          -  Subjects who have donated plasma within 60days prior to drug administration&#xD;
&#xD;
          -  Subjects who have participated in a clinical study within 90days prior to drug&#xD;
             administration&#xD;
&#xD;
          -  Subjects who have received any drugs that might confound the results of the trial in&#xD;
             the opinion of principal investigator (cimetidine within 7days prior to drug&#xD;
             administration)&#xD;
&#xD;
          -  Female subjects who are pregnant, breastfeeding or not using medically acceptable&#xD;
             birth control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Gook Shin, MD, ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2009</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

